The current paradigm of pharmaceutical formulations is focused on the controlled & sustained delivery of a drug for the management of chronic impairments. Since these diseases need daily and multiple intakes of the drug (i.e., twice or thrice a day) and missing a single dose, leads to the poor therapeutic window which governs unpleasant pharmacological response and ultimately patient in-compliance. All over the world, millions of patients are suffering from life-threatening diseases; one of which is “psychosis”, which immensely requires prolong and sustain release of the drug. Moreover, mainstay lacuna with antipsychotic medication is the reoccurrence of the symptoms, and patient adherence on the therapy has been observed. These issues attract scientists to formulate the Controlled Parenteral Antipsychotic (CPA). As per the literature search, significant work has been performed on the development of Novel Controlled Parenteral Formulations (CPFs) for the treatment of psychosis and especially focus has been given to microsphere, esterification, nanoformulation, and salt-based formulation. Reports revealed that all of the above-mentioned formulations have shown enormous potential to enhance the duration of a drug in the body for a longer period in a controlled manner. The development of a drug in any form has shown a great impact on the patient’s life, with tremendous productivity in the Pharma Market. As well as, this has raised the hope to get more efficacious results of both the categories i.e., typical & atypical antipsychotics and limiting the drawbacks of conventional antipsychotic drug delivery. Controlled formulations have also shown the prominent solutions to handle one of the major obstacles that arises due to the Biopharmaceutical Classification System (BCS). Drugs belonging to any of the BCS class can be utilized now with the idea of CPF. In this context, the current paper relies on CPA’s strengths, weaknesses, opportunities, and challenges followed by a compilation of attempt made by scientists on its formulations (microspheres, salt-based, and nanoformulation) which will be one-stop-shop for the researchers working globally in this field to make better improvement on the existing options for psychosis. In summary, this review explains the concept of CPA as a promising option to treat psychosis. Show Keywords: Controlled parenteral antipsychotic, biopharmaceutical classification system, controlled parenteral formulation, long-acting parenteral, microspheres, nanoparticle, salt formation.
 [2] Shahiwala A, Mehta TA, Momin MM. Parenteral drug delivery systems. In vitro and in vivo tools in drug delivery research for optimum clinical outcomes, Ambikanandan M, Aliasgar S, Eds. CRC Press 2018; pp: 301-36.
[3] Chien Y. Novel drug delivery systems 1991. [4] Bari H. A prolonged release parenteral drug delivery system-an overview. Int J Pharm Sci Rev Res 2010; 3(1): 1-11. [5] Agrawal M, Limbachiya M, Sapariya A, Patel G. A review on parenteral controlled drug delivery system. Int J Pharm Sci Res 2012; 3(10): 3657. [6] Sheikh AA. Injectable controlled release drug delivery systems. Asian J Pharm 2016; 10(4): S464-71. [8] Muralidhar P, Bhargav E. Controlled release injectable drug delivery: an over view. Asian J Biomater Res 2017; 3(1): 6-15. [9] Jantzen GM, Robinson JR. Sustained-and controlled-release drug delivery systems. Drugs Pharm Sci 2002; 121: 501-28. [10] Niraj VK, Srivastava N. Sustained and controlled drug delivery system-as a part of modified release dosage form. Int J Res Pharm Nano Sci 2015; 4(5): 347-64. [12] Kostanski JW, Matsuda T, Nerurkar M, Naringrekar VH. inventor; Otsuka Pharmaceutical Co Ltd Curr., assignee. Controlled release sterile injectable aripiprazole formulation and method 2017.United States patent US8030313B2. 2011. [13] Burgess DJ, Wright JC. An introduction to long acting injections and implants In:Long Acting Injections and Implants. Wright JC, Burgess DJ, Eds. New York. Springer Science & Business Media 2012; pp.
1-9. [14] Kalyani M, Surendra P, Sirisha V. Parenteral controlled drug delivery system. Int J Res Pharm Nano Sci 2013; 2: 572-80. [16] Ansel HC, Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery systems. Baltimore: Williams & Wilkins 1995. [23] Dixit N, Maurya SD, Sagar BPS. Sustained release drug delivery system. Ind J Res Pharm Biotechnol 2013; 1(3): 305. [25] Sudhakar M, Kancharla R, Rao VU. A review on sustained release injectable depot drug delivery systems. Int J Adv Pharm Sci 2013; 4: 142-58. [35] Lycett-Smith M, Azar M, Code M. Guidance on the administration to adults of oil-based depot and other long-acting intramuscular antipsychotic injections [41] Brissos S, Veguilla MR, Taylor D,
Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198-219. [43] Motiwala FB, Siscoe KS, El-Mallakh RS. Review of depot aripiprazole for schizophrenia. Patient Prefer
Adherence 2013; 7: 1181-7. [44] Martinez MN, Khan MA. Regulatory issues and challenges associated with the development of performance specifications for modified release parenteral products.In: Long Acting Injections and Implants,. Wright. J. C, Burgess. D. J, Eds.. Springer Science & Business Media 2012; pp.
505-35. [45] Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 2008; 129(2): 79-87. [48] Wang Y, Burgess DJ. Microsphere technologies. In:Long Acting Injections and Implants. Wright. J. C, Burgess. D. J, Eds.. Springer Science & Business Media 2012; pp. 167-94. [49] Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: a review. Int J Res Pharm Chem 2011; 1(4): 1184-98. [55] Talegaonkar S, Mittal A, Parmar S, Aqil M. Aripiprazole loaded polymeric biodegradable microspheres: formulation and in vitro characterization. J Dispers
Sci Technol 2009; 30(8): 1198-202. [56] Hiraoka S, Uchida S, Namiki N. Preparation and characterization of high-content aripiprazole-loaded core-shell structure microsphere for long-release injectable formulation. Chem Pharm Bull (Tokyo) 2014; 62(7):
654-60. [60] Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003; (4): CD004161 [61] D’Souza S, Faraj JA,
Giovagnoli S, Deluca PP. Development of risperidone PLGA microspheres. J Drug Deliv 2014; 2014620464 [62] Nanaki S, Barmpalexis P, Papakonstantinou Z, Christodoulou E, Kostoglou M, Bikiaris DN. Preparation of new risperidone depot microspheres based on novel biocompatible poly (alkylene adipate) polyesters as long acting injectable formulations. J Pharm Sci 2018; 107(11):
2891-901. [66] Rupvate SR, Rokade MM, Sayyad SF, Chaudhari SR. formulation and evaluation of sustained release micro-spheres of paliperidone inventi rapid: Pharm Tech 2012. [71] Park C-W, Lee H-J, Oh D-W, Kang J-H, Han C-S, Kim D-W.
Preparation and in vitro/in vivo evaluation of PLGA microspheres containing norquetiapine for long-acting injection. Drug Des Devel Ther 2018; 12: 711-9. [72] Chaudhary K, Patel MM, Mehta PJ. Long-Acting Injectables: Current Perspectives and Future Promise. Crit Rev Ther Drug Carrier Syst 2019; 36(2): 137-81. [75] Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev 1999; (1): [76] Greco K, Wright J. Aripiprazole, olanzapine and haloperidol pamoate salts 2006. [77] Altamura CA, Colacurcio F, Mauri MC, Moro AR, De Novellis F.
Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14(1): 25-35. [78] Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J. A Double–Blind Controlled Clinical Trial
of Haloperidol Decanoate and Fluphenazine Decanoate in the Maintenance Treatment of Schizophrenia.In: Psychiatry the State of the Art, Pichot P, Ed Springer . 1985; pp. 759-61. [80] McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic
in-patients. Br J Psychiatry 1987; 151(3): 333-6. [81] Zissis NP, Psaras M, Lyketsos G. Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo. Curr Ther Res Clin Exp 1982; 31(4): 650-5. [82] Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand 1980; 62(4): 356-63. [83] Gelders YG, Reyntijens AJ, Ash CW, Aerts TJ. 12-month study of haloperidol decanoate in chronic schizophrenic patients. Int Pharmacopsychiatry 1982; 17(4): 247-54. [84] Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular
haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol 1986; 6(1)(Suppl.): 30S-7S. [96] Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J.
Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21(1): 34-40. [97] Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mølbjerg C.
Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 1991; 84(1): 14-21. [101] Ehret MJ, Sopko MA Jr, Levine A. Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia. Formulary 2008; 43(6): 190-8. [106] Mohanraj VJ, Chen Y. Nanoparticles-a review. Trop J Pharm Res 2006; 5(1): 561-73. [110] Benvegnú DM, Barcelos RCS, Boufleur N, et al. Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 2011; 77(2):
332-6. [111] Yasir M, Sara UVS, Som I. Haloperidol loaded solid lipid nanoparticles for nose to brain delivery: stability and vivo 2015. [112] Imam SS, Ahad A, Aqil M, Akhtar M, Sultana Y, Ali A. Formulation by design based risperidone
nano soft lipid vesicle as a new strategy for enhanced transdermal drug delivery: In-vitro characterization, and in-vivo appraisal. Mater Sci Eng C 2017; 75: 1198-205. [114] Silva AC, González-Mira E, García ML, et al. Preparation, characterization
and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011; 86(1): 158-65. [117] Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and
evaluation of neuroactive drug loaded chitosan nanoparticle for nose to brain delivery: in-vitro characterization and in-vivo behavior study. Curr Drug Deliv 2019; 16(2): 123-35. [118] Dimer FA, Ortiz M, Pase CS, et al.
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects. J Biomed Nanotechnol 2014; 10(6): 1137-45. [119] Vivek K, Reddy H, Murthy RSR. Investigations of the effect of the lipid matrix on drug entrapment, in
vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007; 8(4): 16-24. [120] Sood S, Jawahar N, Jain K, Gowthamarajan K, Nainar Meyyanathan S. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci 2013; 9(1): 26-34. [124] Mittapelly N, Rachumallu R, Pandey G, et al. Investigation of salt formation between memantine and pamoic acid: Its exploitation in nanocrystalline form as long acting injection. Eur J Pharm Biopharm 2016; 101: 62-71. [125] Mittapelly N, Thalla M, Pandey G, et al. Long acting ionically paired embonate based nanocrystals of donepezil for the treatment of Alzheimer’s disease: a proof of concept study. Pharm Res 2017; 34(11): 2322-35. [132] Julie KB. inventor; Eli Lilly and Co Inc., assignee. Olanzapine pamoate dihydrate. United States patent US7932249B2 2011 April.. [133] Korinde AJ. inventor.Controlled release paliperidone composition.WO2011018246A2. 2011 Feb. [134] Marc KJF, Willy MACD, Esther DGB. inventor; Janssen Pharmaceutica NV Inc., assignee Aqueous suspensions of submicron 9- hydroxyrisperidone fatty acid esters United States patent US9320707B2. 2016 April; [135] Dierk W, Alexandra G, Markus A. inventor. Injectable depot formulation comprising crystals of iloperidone United States patent US20090099232A1. 2009 April; [136] Janusz WK, Takakuni M, Manoj N, Vijay HN. inventor; Otsuka Pharmaceutical Co Ltd Inc., assignee.Controlled release sterile injectable aripiprazole formulation and method. United States patent US8952013B2. 2015 Feb; [137] Steven JS, Karen IW, Raquel EG, Robert HL. inventor; University of Pennsylvania Inc., assignee. Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use. United States patent US8758795B2. 2014 June; Article Metrics 8 What are the benefits of taking antipsychotic medication?Antipsychotic drugs don't cure psychosis but they can help to reduce and control many psychotic symptoms, including: delusions and hallucinations, such as paranoia and hearing voices. anxiety and serious agitation, for example from feeling threatened. incoherent speech and muddled thinking.
What is the benefit of atypical antipsychotic medications?Many clinicians and basic scientists believe that the atypical APDs are effective only for delusions and hallucinations. However, as adjunctive agents, they are also effective for treating aggression, anxiety, mood symptoms, and obsessive-compulsive symptoms, to name other established common uses (18).
What antipsychotics can be given by injection?How Do They Work?. Aripiprazole (Abilify Maintena). Aripiprazole lauroxil (Aristada). Fluphenazine (Prolixin). Haloperidol (Haldol). Olanzapine pamoate (Zyprexa Relprevv). Paliperidone (Invega Sustenna, Invega Trinza). Risperidone (Risperdal Consta). What should you monitor when taking antipsychotics?Patients taking antipsychotics are at increased risk for developing metabolic syndrome, which subsequently increases their risk for ASCVD. Weight, fasting plasma glucose/A1c, lipids, and BP should be routinely monitored in patients taking antipsychotics.
|
Which is a benefit of taking a parenteral formulation of an antipsychotic medication
zusammenhängende Posts
Urheberrechte © © 2024 paraquee Inc.
